Progression of erectile function in men with chronic obstructive pulmonary disease: a cohort study by �삤�쓽湲�
RESEARCH ARTICLE Open Access
Progression of erectile function in men
with chronic obstructive pulmonary
disease: a cohort study
Eui Geum Oh1 and Jae Yong Yoo2*
Abstract
Background: Although sexual function is a quality of life aspect that is markedly affected in males with chronic
obstructive pulmonary disease (COPD), this topic has not attracted much attention and research on this matter is
lacking. In this study, we investigated longitudinal changes in the erectile function of men with COPD in order to
identify latent groups and influencing factors.
Methods: A total of 185 men with COPD from the Korean Obstructive Lung Disease study, which was conducted
from 2005 to 2013, were analyzed in this study. Data on their erectile function, based on the International Index of
Erectile Function-5, were collected over a period of 4 years. Growth mixture modeling and logistic regression
analysis were used to determine the factors predicting distinct erectile function changes over time.
Results: Overall, subjects’ erectile function slightly improved in the first year and then gradually worsened over
time. Using growth mixture modeling, we identified four distinct latent groups, which we labeled as follows:
“consistently maintained normal erectile function” (9.7%), “rapidly worsened and then rapidly improved” (9.2%),
“gradually improved in the early stage and then gradually worsened” (36.8%), and “consistently maintained poor
erectile function” (44.3%). Progression of erectile function was significantly associated with age, economic status,
and self-rated health status.
Conclusions: This suggests that comprehensive patient care involving the management of COPD as well as erectile
dysfunction in patients with chronic respiratory disease is important from a prophylactic perspective and should be
developed in accordance with the characteristics of the disease process.
Keywords: Chronic obstructive pulmonary disease, Longitudinal study, Male, Erectile dysfunction
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disorder characterized by airflow limitation that
is not fully reversible, and is accompanied by chronic in-
flammation of the airway and lungs [1]. In 2016, COPD
was the third most common cause of death worldwide
[2]. In Asia in particular, the rate of increase in the inci-
dence of COPD is exacerbated by high smoking rates;
exposure to indoor and outdoor air pollution arising
from biomass fuel combustion; and frequent exposure to
yellow dust, particulate matter, and industrial dust [3].
The global COPD prevalence rates are estimated to be 7.5–
10.3%, whereas in Korea, the prevalence is reported to be
13.7% (men: 23.3%, women: 6.5%) among individuals
aged > 40 years, according to the 5th Korea National
Health and Nutrition Examination Survey [4]. The consid-
erably higher COPD prevalence rate in Korea is thought to
be related to high smoking rates and exposure to tubercu-
losis, which are both risk factors for COPD, along with a
rapidly aging population [3–5]. Although the smoking rate
among Korean adults decreased from 66.7% in 1995 to
36.2% in 2013, it remains the highest among Organization
for Economic Co-operation and Development (OECD)
countries [4], and Korea has the highest rate of tuberculosis
outbreaks and deaths among OECD countries [3].
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jaeyongyoo@chosun.ac.kr
2Department of Nursing, College of Medicine, Chosun University, Gwagnju,
Korea, 309 Pilmundae-ro, Dong-gu, Gwangju 61452, Korea
Full list of author information is available at the end of the article
Oh and Yoo BMC Pulmonary Medicine          (2019) 19:139 
https://doi.org/10.1186/s12890-019-0902-y
The relatively high rate of COPD in Korea poses a
financial burden due to COPD-related health and med-
ical expenses, and leads to deterioration in the quality
of life (QoL). The ultimate goal of health management
for patients with COPD is to improve their QoL, a
major subjective marker of health status that is used to
assess the effects of treatment and interventions [3, 6].
Men exhibit an increased prevalence of COPD after 60
years of age [7, 8], and sexual function is a QoL aspect
that is markedly affected in men with COPD [9, 10].
The mechanism underlying sexual dysfunction in
COPD patients is not yet fully understood. Smoking,
chronic hypoxia, aging, systemic/endothelial inflamma-
tion, hormonal imbalances (hypogonadism or lower
testosterone levels), decreased physical activity, fear of
breathing difficulty, cardiovascular disease, and medica-
tion side effects are considered to be possible contrib-
uting factors [11]. Respiratory or physical symptoms,
such as dyspnea, cough, weakness, and reduced phys-
ical activity affect both erectile function and sexual
activity, which lowers the QoL of COPD patients. For
many patients, the loss of erectile function triggers a
sense of shame, as they perceive that they can no longer
function as men, which can reduce their self-esteem
and cause depression [12].
Despite these detrimental consequences, the effect of
COPD on erectile function in men is underappreciated
in clinical practice, partly because patients often feel
uncomfortable talking about their erectile function with
healthcare providers [7, 9, 10]. In Korea and other
Asian countries, discussion of sexual issues is a cultural
taboo: only 2% of men and women in Korea discuss
their sexual health problems with medical personnel
[13]. Therefore, information regarding erectile dysfunc-
tion among male patients with COPD is sparse and
erectile dysfunction tends to be underreported in Korea
relative to other countries [3, 14, 15]. According to the
Massachusetts Male Aging Study, a large epidemio-
logical study performed in the US, 52% of 1,709 men
aged 40–70 years experienced sexual dysfunction at
some point during their life [16]. In an epidemiological
study of > 10,000 men aged 20–75 years in five Asian
countries, including Korea (the Asian Men’s Attitudes
to Life Events and Sexuality study), researchers found
that the rate of self-reported sexual dysfunction was
6.4% [15].
Sexual function is an indicator of health and QoL,
and it changes over time. However, previous studies
have primarily investigated the prevalence of erectile
or sexual function and the correlations with patient
characteristics [9, 10, 17]. Furthermore, most of these
studies were cross-sectional; therefore, researchers
cannot fully explain how patient characteristics affect
progression in erectile function. Since the physical
functioning of patients with COPD gradually deterio-
rates over time, it is important to understand these
dynamic changes in health status and to plan patient-
centered care and management accordingly [18].
Therefore, in this study we used the Korean Obstruct-
ive Lung Disease (KOLD) cohort data to investigate the
patterns of change over time in the erectile function of
men with COPD. We aimed to identify factors that
affect these patterns, as a basis for the development of
strategies for patient-centered care and intervention pro-
grams. The following research questions were addressed:
(1) Are there latent categories among male patients
with COPD, defined by distinct longitudinal
patterns of erectile function levels?
(2) How many latent groups exist, and what are the
associations between distinct erectile function
patterns and subjects’ socio-demographic, disease-
related physical/functional status, and cognitive
variables?
(3) If there are multiple baseline erectile functions,
what are the putative factors for discriminating
these functions?
(4) If there are multiple distinct patterns, what are the
factors that affect longitudinal patterns?
Methods
Study design
This study was a secondary analysis of the data of 185
men with COPD from the KOLD cohort. The KOLD
cohort was established by 16 secondary or tertiary hospi-
tals in South Korea between 2005 and 2013, for the
purpose of building a systematic diagnostic model of
COPD and detecting comprehensive predictors of
COPD.
Subjects
The following subjects were included in the study: men
aged ≥40 years, with chronic respiratory symptoms, and
who were diagnosed with COPD by a pulmonary phys-
ician according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines [1]. Sub-
jects were excluded if they 1) had been diagnosed with a
second serious health conditions (e.g., heart failure,
severe cerebrovascular disease, chronic urological
disease, or renal failure); 2) were taking medications or
participating in a separate program that affected erectile
function; and 3) had undergone lung surgery, such as a
lobectomy. A total of 144 patients were excluded
because they did not undergo pulmonary function
testing at baseline, or had fewer than two follow-up
erectile function values. Thus, 185 of the 329 original
patients comprised the subjects of this study.
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Measurements
The erectile function of men with COPD was
assessed using the Korean version of the International
Index of Erectile Function-5 (IIEF-5) [19]. The IIEF-5
is a self-administered questionnaire scored on a five-
point Likert scale that contains five items related to
erectile and orgasmic functioning, and its validity and
reliability are internationally recognized [20]. Exam-
ples of the items in the IIEF-5 include: “During sexual
intercourse, how difficult was it to maintain your
erection to completion of intercourse?” and “When
you attempted sexual intercourse, how often was it
satisfactory for you?” The total score ranges from 1
to 25 points. The subjects were classified into five
sexual function groups according to Rosen’s cutoff
value [20]: none (IIEF-5 score: 25–22), mild (21–17),
mild-moderate (16–12), moderate (11–8), and severe
(7–1). In this study, Cronbach’s alpha for the IIEF-5
tool was 0.86. In cases wherein self-reporting was dif-
ficult or rejected, a trained researcher collected the
necessary data via interview.
This study was based on the “Chronic illness trajec-
tory model” by Corbin and Strauss [21]. In this
model, chronic diseases are not fixed, but are consid-
ered to be a process that can unfold with various
trajectories or patterns over time. Socio-demographic,
disease-related physical/functional, and cognitive fac-
tors may be associated with longitudinal changes in
individuals’ health levels. In this model, it is import-
ant for the patient, family, and health professionals to
understand and manage the perceptions of the indi-
vidual and the contextual situations, treatment/care
plans, and disease progression that affect the chronic
disease status. Based on this model, the following
independent variables were measured using structured
questionnaires and clinical test results. Demographic
characteristics included age, education level, smoking
status, current medications, and economic status.
Symptom variables included the number of respiratory
symptoms, sleep disturbance, and the level of anxiety
and depression, as measured by the Beck Anxiety
Inventory (BAI) [22]. The BAI consists of 21 multiple-
choice questions regarding anxiety symptoms that the
subject may have experienced during the past month
(e.g., “How much you have been bothered by fear of
losing control?”). The Beck Depression Inventory
(BDI) consists of 21 items designed to evaluate symp-
toms and attitudes associated with depression, such
as “I feel the future is hopeless and that things
cannot improve.” The Beck items are scored on a
four-point scale ranging from 0 to 3, with a higher
score indicating higher severity. Self-rated health was
measured by a single item; “What do you think of
your overall health at present?” Responses were
scored as 0 (excellent), 1 (good), 2 (fair), 3 (poor),
and 4 (very poor), with a higher score indicating a
poorer status.
Functional variables included pulmonary function; the
Body mass index, airflow Obstruction, Dyspnea, and
Exercise capacity (BODE) index, a multidimensional
prognostic tool for COPD [23]; disease severity; number
of comorbidities; and exacerbations in the last year.
Pulmonary function tests were performed using spirom-
etry (2130 or Vmax 22, SensorMedics, Yorba Linda, CA;
PFDX, MedGraphics, Saint Paul, MN, USA), according
to the American Thoracic Society (ATS) guidelines [1],
and evaluated the forced vital capacity (FVC), forced
expiratory volume in 1 s (FEV1), and ratio of FEV1 to
FVC (FEV1/FVC). The BODE index ranges from 0 to 10,
with a higher score indicating a poorer status. Airflow
obstruction status was evaluated using the FEV1 value.
Dyspnea was assessed using the Modified Medical
Research Council Dyspnea Scale, and exercise capacity
was measured by the six-minute walk distance test,
according to the ATS guidelines [24]. The subjects were
scored from 0 to 3 for each threshold value. COPD
severity was assessed using the GOLD guidelines [1, 6].
Data collection and statistical analysis
All data were obtained at baseline and subsequently
every 12 months over a 4-year period by trained clin-
ical researchers using the ATS standardized guidelines
[1]. Researchers at each of the 16 participating insti-
tutions were trained to collect data according to the
standardized data collection protocol. Research super-
visors periodically supervised quality control of the
data collection.
We hypothesized that individuals could be clustered
into smaller groups according to the patterns of
change in the erectile function status [25]. We ap-
plied growth mixture modeling (GMM) to identify
patterns of change using the longitudinal cohort data
[26]. GMM is based on a conventional growth model
involving the estimation of growth representative of
the entire population. However, the patterns of
change in the erectile function levels of COPD pa-
tients may not be the same for all patients. Nylund et
al. have emphasized that certain subgroups of individ-
uals exhibit growth trajectories (reflected in the
model parameters) that differ significantly from the
estimated trajectory of the population [27]. We used
STATA 12.0 to construct a GMM with linear and
quadratic effects of time to distinguish latent sub-
groups according to patterns of change in the erectile
function levels of the COPD patients. An analysis was
then performed to determine the factors influencing
subgroup membership.
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The statistical analyses were performed in three
stages, as follows: In the first stage, using the IIEF-5
scale as a continuous measure, GMM was used to
identify naturally occurring trajectories in the changes
in erectile function over time. In the GMM, we used
all available IIEF-5 scores for each of the participants
at five time points (baseline, and 12, 24, 36, and 48
months later) to identify subgroups of individuals
with relatively similar trajectories. For each distinct
latent group, different intercepts (i.e., baseline values)
and slope parameters (reflecting patterns of change
over time) were estimated to describe the longitudinal
patterns in outcome measures. One major benefit of
GMM is that it can model non-linear and linear tra-
jectories [25]. We used cubic polynomials to model
the shape of each latent trajectory as follows:
Erectile function ¼ I þ a1T1 þ a2T2 þ a3T3;
where Erectile function is the predicted IIEF-5 score, I
is the predicted intercept, T is the time at which the
variable is measured, and a1, a2, and a3 are linear, quad-
ratic, and cubic parameters, respectively.
We used unconditional models, in which no independ-
ent variables were included, to determine the optional
number of latent erectile function groups for describing
the patterns of change. We increased the number of
groups sequentially to a total of five and compared the
resulting models. There was no absolute criterion for de-
termining how many groups to include in the GMM;
however, the optimal number of latent groups can be de-
termined by considering model fit criteria. Therefore, we
considered the Akaike Information Criterion (AIC) and
the Bayesian Information Criterion (BIC) [25, 26]. Fol-
lowing Nagin’s approach [26], the smaller the absolute
values of the AIC and BIC, the better the model. En-
tropy is another good indicator, because the probability
of belonging to each latent group approaches 1. In
addition to comparing models based on these criteria,
when finally classifying potential groups, we required the
minimum sample size in each group to be 10, which is
clinically meaningful, as a model with too few cases in a
subgroup is not reliable [25].
In the second statistical analysis stage, we tested for
differences between groups with distinct erectile func-
tion patterns with regard to patients’ socio-demographic,
disease-related physical/functional status, and cognitive
variables. For descriptive statistics, we used the mean
and standard deviation for continuous variables and pro-
portions for categorical variables. To compare the char-
acteristics of the subjects across latent groups,
categorical variables were analyzed using chi-square
tests, and continuous variables were analyzed using ana-
lysis of variance and post-hoc Scheffe’s test.
In the third statistical analysis stage, two logistic
regression analyses were conducted to identify corre-
lates of baseline erectile function and factors predict-
ing different erectile function trajectories during the
observation period. Socio-demographic, physical/func-
tional, and cognitive factors were included as inde-
pendent variables.
In the first logistic regression analysis, ordinal logistic
regression was used to determine the influence of puta-
tive predictive factors on baseline erectile function. In
practice, the baseline erectile function level of a subject
is determined at the time of enrollment in a medical fa-
cility or at the beginning of COPD treatment. Based on
these baseline values, patients with COPD with erectile
function issues can be identified early and access to indi-
vidualized interventions can be ensured. In the second
logistic regression analysis, multinomial logistic regres-
sion was performed to assess the influence of factors
predicting the progression in the erectile function. These
factors can guide treatment strategies for improving
long-term health status and sexual function-related
symptoms, leading to improved symptoms and QoL.
The results are summarized as odds ratios (ORs) with
95% confidence intervals (CIs). P < 0.05 was considered
statistically significant. SPSS 22.0 and STATA 12.0 were
used for data analysis. The entire analysis of this study
was conducted under the consultation and review of
biostatisticians.
Ethics
This cohort protocol was approved by the institutional
review board of all participating hospitals (Approval No
2005–0345). All subjects were provided with oral and
written explanations of the study processes. Written in-
formed consent was provided by each participant.
Results
General characteristics of subjects
The subjects’ characteristics are summarized in Table 1.
The mean age of the subjects was 65.4 ± 7.3 years
(range: 45–84 years), and 108 (58.4%) subjects were
aged ≥65 years. Fifty-nine (31.9%) subjects were current
smokers, and the mean number of smoking pack-years
was 22.6 ± 12.8. Over 80% of the patients had moderate
to severe ventilator defects, based on the FEV1 value.
According to the combined COPD assessment criteria
(symptoms, risk of exacerbation, and lung function test
results) [6], 37.8% of patients were classified as GOLD
A, 24.3% as GOLD B, 10.8% as GOLD C, and 27.0% as
GOLD D.
We administered a questionnaire that included a
question on whether pharmacological therapy for COPD
treatment was provided. The researchers at the cohort-
registered hospital reviewed the patients’ medical records
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to determine the type of medication currently being
administered. At the time of cohort registration, 72.4%
(n = 134) of the patient were receiving pharmacological
treatment, namely beta-2 agonists, muscarinic antagonists,
inhaled corticosteroid/long acting beta-2 agonists, methyl-
zanthines, and mucolytics. We assumed the influence of
any changes in these medications during the study period
to be minimal.
The mean post-bronchodilator FEV1 was 59.9 ± 18.3%,
and the mean FEV1/FVC was 46.8 ± 10.6% of the pre-
dicted values. The mean baseline BODE index and IIEF-
5 scores were 2.08 ± 1.79 and 10.7 ± 5.3, respectively. Ac-
cording to the IIEF-5 criteria [20], 7.6% individuals had
normal, 17.7% had mild, 22.2% had mild–moderate,
14.1% had moderate, and 38.4% had severe erectile
dysfunction.
Progression of erectile function
Notably, 92.4% of the patients had mild to severe erect-
ile dysfunction at baseline. Although the erectile func-
tion of these patients partially improved during the first
year after their registration in the cohort, it tended to
worsen thereafter. The estimated intercept of erectile
function was 11.6 (standard error [SE] = 0.6), and the
slope was − 0.7 (SE = 0.1) for all subjects. Despite some
fluctuation, these values indicated that erectile function
gradually worsened over time. In the GMM analyses
with different numbers of latent groups, the AIC and
BIC values were the lowest for four latent groups. The
possible models of erectile function trajectories, with
the number of subjects in each group and model fit in-
dices, are summarized in Table 2.
The four groups were defined according to the ob-
served patterns of change: “Group A” consistently main-
tained normal erectile function (9.7%, n = 18), “Group B”
had erectile function that rapidly worsened and then
rapidly improved (9.2%, n = 17), “Group C” had erectile
Table 1 General characteristics of the subjects at baseline (n= 185)
Characteristics (continuous variables) Mean SD
Age (years) 65.4 7.3
BMI (kg/m2) 23.1 3.3
Income (US dollars/month) 2,230.9 1,850.2
Smoking history (pack year) 22.6 12.8
Number of comorbidities 0.5 0.4
Number of respiratory symptoms 2.6 1.4
Number of exacerbation in last year 0.77 2.45
FEV1 (L) 1.62 0.53
FEV1 (predicted %) 59.94 18.34
FVC (L) 3.45 0.78
FEV1/FVC (%) 46.84 10.66
6MWD (m) 447.2 78.4
mMRC dyspnea scale score 1.5 0.9
BODE index score 2.08 1.79
BAI score 6.01 7.55
BDI score 9.10 9.37
Self-rate health status 2.25 0.78
IIEF-5 score at baseline 10.79 5.30
IIEF-5 score at 12 months 10.92 5.28
IIEF-5 score at 24 months 9.68 5.69
IIEF-5 score at 36 months 8.45 4.38
IIEF-5 score at 48 months 7.72 4.39
Characteristics (categorical variables) n %
Education level
≥ bachelor’s degree 41 22.1
high school 66 35.7
≤middle school 78 42.2
Current smoking
yes 59 31.9
no 126 68.1
Current medication
yes 134 72.4
no 51 27.6
Sleep disturbance
yes 53 28.6
no 132 71.4
Emergency room visit in last year
yes 35 18.9
no 150 81.1
Severity of COPD based on
combined COPD assessment
GOLD A (low risk, fewer symptoms) 70 37.8
GOLD B (low risk, more symptoms) 45 24.3
GOLD C (high risk, fewer symptoms) 20 10.8
Table 1 General characteristics of the subjects at baseline (n= 185)
(Continued)
Characteristics (continuous variables) Mean SD
GOLD D (high risk, more symptoms) 50 27.0
Baseline erectile function (IIEF-5 score)
Normal (25–22) 14 7.6
Mild (21–17) 33 17.7
Mild-moderate (16–12) 41 22.2
Moderate (11–8) 26 14.1
Severe (≤7) 71 38.4
SD standard deviation, BMI body mass index, FEV1 forced expiratory volume in
1 s, FVC forced vital capacity, 6MWD six-minute walk test, mMRC modified
Medical Research Council, BODE body mass index (B), the degree of airflow
obstruction (O), functional dyspnea (D), exercise capacity (E) index, GOLD
global initiative for chronic obstructive lung disease, IIEF-5 International index
of erectile function-5, COPD chronic obstructive pulmonary disease, BAI beck
anxiety inventory, BDI beck depression inventory
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function that gradually improved during the early stage,
but then gradually worsened over time (36.8%, n = 68),
and “Group D” consistently had poor erectile function
(44.3%, n = 82) (Fig. 1). Differences in the subjects’ char-
acteristics according to the four latent groups are sum-
marized in Table 3.
Factors affecting baseline erectile function
The four groups were further divided into three clusters
according to the baseline erectile function level: Cluster
1 (normal baseline function, Group A, 9.7%, n = 18),
Cluster 2 (mild to moderate dysfunction at baseline,
Groups B and C, 46.0%, n = 85), and Cluster 3 (severe
Table 2 Model fit statistics and parameter estimates for distinct trajectories of erectile function (IIEF-5)
Group n AIC BIC Log- likelihood Intercept (SE) Linear slope (SE) Quadratic slope (SE)
1 185 2640.77 2648.82 − 2635.77 11.685*** (0.605) − 0.725*** (0.193) 0.011 (0.161)
2 107 2512.49 2528.59 − 2502.49 7.515*** (0.671) − 0.737** (0.197) 0.143 (0.169)
78 17.506*** (0.770) −0.690* (0.235) −0.278 (0.203)
3 86 2479.59 2503.74 − 2464.59 6.018*** (0.697) − 0.594** (0.206) 0.126 (0.173)
78 15.346*** (0.698) −1.026*** (0.215) −0.198 (0.183)
21 21.297*** (1.414) −0.188 (0.411) − 0.170 (0.325)
4 82 2461.49 2501.75 − 2470.84 5.152*** (0.823) − 0.395 (0.231) −0.112 (0.180)
17 16.300*** (2.090) −2.260*** (0.716) 2.438*** (0.523)
18 21.679*** (1.330) −0.193 (0.410) − 0.155 (0.311)
68 14.706*** (1.188) −0.416 (0.392) − 0.632** (0.223)
5 22 2470.84 2503.04 − 2461.49 5.153** (2.345) −0.395 (0.630) −1.527*** (0.359)
56 5.152*** (1.181) − 0.395 (0.323) − 0.079 (0.177)
36 16.300*** (2.101) −2.260** (0.718) 0.076 (0.305)
52 14.706*** (1.190) −0.416 (0.393) 2.377*** (0.458)
19 21.679*** (1.339) −0.194 (0.411) −0.146 (0.311)
Selected model Group name n (%)
Four group models Group A: consistently good erectile function 18 (9.7)
Group B: rapidly worsened and then rapidly improved 17 (9.2)
Group C: gradually improved and then gradually worsened 68 (36.8)
Group D: consistently poor erectile function 82 (44.3)
IIEF-5 International index of erectile function-5, AIC akaike information criterion, BIC Bayesian information criterion, SE standard error
*p < .05, **p < .01, ***p < .001
Fig. 1 Four latent groups of longitudinal erectile function patterns
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dysfunction at baseline, Group D, 44.3%, n = 82). Clus-
ter 1 was set as the reference cluster for the ordinal logis-
tic regression. Factors that increased the likelihood of
belonging to a higher-dysfunction cluster at baseline were
older age (OR 1.14, 95%CI 1.08–1.21), lower economic
status (OR 1.27, 95%CI 1.05–1.57), higher BODE index
(OR 1.31, 95%CI 1.02–1.68), and poorer self-rated health
status (OR 1.69, 95%CI 1.01–2.85) (Table 4).
Factors affecting progression of erectile function
Multinomial logistic regression was performed to inves-
tigate predictors of the progression of erectile dysfunc-
tion. Group A was again set as the reference group.
Distinct patterns were significantly associated with age
(Group B vs. A: OR 1.23, 95%CI 1.04–1.44; Group D vs.
A: OR 1.26, 95%CI 1.10–1.45), economic status (Group
C vs. A: OR 1.22, 95%CI 1.11–1.32; Group D vs. A: OR
1.28, 95%CI 1.12–1.53), and self-rated health status
(Group B vs. A: OR 5.59, 95%CI 1.13–2.76; Group C vs.
A: OR 5.57, 95%CI 1.41–2.19; Group D vs. A: OR 6.67,
95%CI 1.62–2.75) (Table 5).
Discussion
This study investigated the progression of the erectile
function of men with COPD over the course of 4 years,
in order to identify latent groups and determine the
influencing factors. The men with COPD included in
this study exhibited slight improvement in the total
mean erectile function score during the first year, but
this score tended to worsen gradually over time. We
identified four distinct latent groups based on individ-
ual changes in erectile function over time.
Sexual dysfunction in elderly patients with chronic-
ally weakened physical and mental conditions has not
received much attention [7, 9, 13]. In addition, there
are social prejudices and a lack of understanding of
sexual behavior and satisfaction in patients with chronic
illness who still experience sexual desire [10, 13, 17]. Men
with COPD experience significantly lower erectile
function and less sexual satisfaction than do men
without COPD, making it difficult to have a healthy
sexual life; in turn, erectile dysfunction hinders dis-
ease management and can result in depressive symp-
toms and reduced QoL [10, 28]. Collins’ study of 90
patients with moderate to severe COPD revealed that
≥74% of the patients had sexual health problems [7].
In a Taiwanese cohort study of 57,928 participants
[28], patients with COPD had 1.88-fold more sexual
problems than did patients without COPD. These
findings suggest that active care and management of
erectile function and sexual satisfaction is required in
men with COPD.
Table 4 Results of ordinal logistic regression analysis of factors affecting the baseline erectile function level
Variables Category Cluster 1 (normal
baseline,
Group A) Reference
Cluster 2 (mild to
moderate baseline,
Group B & C)
Cluster 3 (severe
baseline, Group D)
Cluster 1 vs.
Cluster 2 and 3
(n = 18, 9.7%) (n = 85, 46.0%) (n = 82, 44.3%) Odd ratio 95% CI p
Age (mean ± SD, years) 59.9 ± 6.0 62.9 ± 7.1 69.2 ± 5.9 1.14 1.08–1.21 < 0.001
Education (n, %) ≥bachelor’s degree 7 (38.9) 12 (14.1) 22 (26.8) 0.96 0.58–1.62 0.821
high school 8 (44.4) 37 (43.5) 21 (25.6)
≤middle school 3 (16.7) 36 (42.4) 39 (47.6)
Income (n, %) ≥2,000 14 (77.8) 39 (45.9) 32 (39.0) 1.27 1.05–1.57 0.021
(US dollars/month, n) < 2,000 4 (22.2) 46 (54.1) 50 (61.0)
Current smoker (n, %) yes 6 (33.3) 29 (34.1) 24 (29.3) 0.95 0.47–1.92 0.905
no 12 (66.7) 56 (65.9) 58 (70.7)
Number of comorbidities 0.67 ± 0.68 0.65 ± 0.61 0.62 ± 0.68 1.17 0.72–1.78 0.527
Number of symptoms 2.72 ± 1.27 2.62 ± 1.40 2.65 ± 1.36 0.93 0.74–1.12 0.596
BODE index sore 1.17 ± 1.30 1.88 ± 1.65 2.48 ± 1.93 1.31 1.02–1.68 0.032
Sleep disturbance (n, %) yes 4 (22.2) 29 (34.1) 20 (24.4) 0.64 0.29–1.39 0.265
no 14 (77.8) 56 (65.9) 62 (75.6)
Exacerbation (n, %) yes 2 (11.1) 14 (16.5) 19 (23.2) 0.88 0.35–2.19 0.787
in last year no 16 (88.9) 71 (83.5) 63 (76.8)
BAI score 5.83 ± 5.80 5.89 ± 8.14 6.17 ± 7.31 1.02 0.96–1.08 0.519
BDI score 8.00 ± 9.71 8.01 ± 7.95 10.48 ± 10.53 0.99 0.94–1.04 0.753
Self-rated health status 1.89 ± 0.76 2.24 ± 0.73 2.35 ± 0.81 1.69 1.01–2.85 0.047
SD standard deviation, BODE body mass index (B), the degree of airflow obstruction (O), functional dyspnea (D), exercise capacity (E) index, BAI beck anxiety
inventory, BDI beck depression inventory, CI confidence interval
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Additionally, the prevalence and severity of COPD in-
creases with age [4, 5, 8]. We found that subjects in the
persistently poor erectile function group had a higher
mean age than those in the persistently good erectile
function group. Previous studies have also reported an
association between age and sexual function in patients
with chronic illness [7, 9, 12]. The recently revised
guidelines for COPD management emphasize the im-
portance of regular assessment and management of sub-
jective health status [6]. This includes verifying the
symptoms subjectively experienced by the patient and
identifying the degree of their impact on daily life by
means of a COPD assessment test (CAT) [6]. Therefore,
outpatients or hospitalized COPD patients should be en-
couraged to utilize subjective patient assessment tools,
such as the CAT and IIEF-5, and to undergo objective
clinical tests, such as laboratory tests or pulmonary
function tests. When a physician or a clinical nurse first
assesses elderly male COPD patients, erectile function
evaluation using the IIEF-5 should be considered essen-
tial. Healthcare professionals should not overlook the
area of sexual health, as it is an important aspect of QoL
in older patients. Erectile dysfunction is a problem that
can negatively affect sexual satisfaction for both men
and women. However, most previous studies have fo-
cused on male impotence, and only two studies included
women with COPD [17, 29]. Kaptein et al.’s study [17]
also revealed that more than two-thirds of patients do
not express their thoughts regarding sexual function to
their physicians or partners. Attention should be
afforded to the sexual function and sexual satisfaction of
COPD female patients as well as male patients, and
these subjects should be investigated in future studies.
The erectile function of the subjects included in the
current study tented to improve in the first year and
then deteriorate again. As there have been no prior stud-
ies on the longitudinal analysis of erectile function in
male COPD patients, various interpretations are pos-
sible. The subjects included in the study were first diag-
nosed with COPD by a physician and enrolled in the
cohort, and then visited outpatient clinics of medical
facilities regularly to receive optimal treatment including
non-pharmacological treatments. In this study, the
GOLD A group with few symptoms comprised 37.8% of
the patients, and 68.2% corresponded to GOLD stage 1
and 2 based on the FEV1 values. Therefore, it is likely
that interventions such as health education and correc-
tion of health-related lifestyle habits including smoking
cessation were more frequent in the first year of diagno-
sis. This may also be the result of the limitations of self-
administered questionnaires. If the subjects in the cohort
report severe erectile dysfunction, this may be the result
of a regression to the mean if erectile dysfunction is a
fluctuating condition. It may also be due to the Haw-
thorne effect occurring in the interaction with the physi-
cians during enrolment. To more accurately observe
these fluctuations, it would be beneficial to analyze the
difference in erectile function changes according to the
time of diagnosis (early-stage vs. end-stage).
In this study, we identified four distinct latent groups:
“consistently maintained normal erectile function group”
(9.7%), “rapidly worsened and then rapidly improved
group” (9.2%), “gradually improved in the early stage,
and then gradually worsened group” (36.8%), and “con-
sistently maintained poor erectile function group”
(44.3%), based on GMM analysis of repeated IIEF-5
Table 5 Results of multinomial logistic regression analysis of factors affecting the longitudinal pattern of erectile function
Variables Group A vs. Group B Group A vs. Group C Group A vs. Group D
Odd ratio 95% CI p Odd ratio 95% CI p Odd ratio 95% CI p
Age 1.23 1.04–1.44 0.013 1.03 0.91–1.16 0.622 1.26 1.10–1.45 0.001
Education 0.92 0.66–1.21 0.545 0.90 0.72–1.43 0.588 0.88 0.57–1.33 0.432
Income 0.99 0.98–0.99 0.006 1.22 1.11–1.32 0.003 1.28 1.12–1.53 0.005
Current smoking 0.85 0.13–5.59 0.868 1.53 0.36–6.44 0.561 1.32 0.28–6.04 0.722
Number of comorbidities 1.22 0.92–1.67 0.452 1.02 0.96–1.23 0.744 1.34 0.98–1.72 0.343
Number of symptoms 0.96 0.49–1.93 0.917 0.70 0.39–1.26 0.241 0.78 0.43–1.42 0.424
BODE index score 1.72 0.83–3.58 0.141 1.16 0.62–2.18 0.634 1.71 0.90–3.25 0.901
Sleep disturbance 1.23 0.15–9.90 0.848 1.15 0.19–6.94 0.876 0.66 0.10–4.27 0.669
Exacerbation in last year 0.82 0.43–1.52 0.528 0.96 0.74–1.24 0.774 1.03 0.78–1.36 0.822
BAI score 1.07 0.92–1.23 0.390 1.01 0.90–1.14 0.789 1.03 0.91–1.17 0.593
BDI score 0.93 0.79–1.07 0.330 0.94 0.83–1.05 0.267 0.95 0.83–1.07 0.423
Self-rated health status 5.59 1.13–27.6 0.034 5.57 1.41–21.9 0.014 6.67 1.62–27.5 0.009
BODE body mass index (B), the degree of airflow obstruction (O), functional dyspnea (D), exercise capacity (E) index, BAI beck anxiety inventory, BDI beck
depression inventory, CI confidence interval
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measures. This can facilitate our understanding of the
characteristics of and differences among patients, which
is critical when devising patient-centered care strategies
and interventions that are tailored to patients’ needs
[18]. We also identified factors that predict which erect-
ile function change group male COPD patients are likely
belong to.
Older age, lower economic status, and poorer subject-
ive health status were identified as factors that affect the
progression of erectile function in men with COPD.
Having patients assess these changes themselves allows
them to realistically predict how the level of erectile
function will change during the course of their disease.
These realistic predictions can lead to self-identification
of their current health condition, raise awareness of their
subjective health status, and motivate them to utilize re-
sources and implement health behaviors necessary to
improve their condition. Subjective symptoms and the
perception of health are highly important because they
can affect the health status and health-related lifestyle
[18, 21]. As outpatient visits should take place on a regu-
lar basis due to the nature of COPD, it is also recom-
mended that a cubicle be constructed for patients to
evaluate their own levels of sexual health. The cubicle
program, such as a Kiosk system, needs to be configured
such that most patients are able to respond with a sim-
ple electronic format with a touch screen, considering
their age. Such a Kiosk system needs to be installed in a
separate space in an outpatient clinic or inpatient ward
and made of opaque glass walls. This can protect the pa-
tient’s privacy and allow for self-assessment of erectile
function and sexual health, which patients consider sen-
sitive information, in a more comfortable environment.
If it worsens, convey this to the medical personnel and
receive sex counseling. They should be guided to in-
crease physical activity in everyday life, to participate in
leisure activities in the community, and to make use of
available resources, because the subjective health level is
affected by these factors. Nurse-led recreational pro-
grams for inpatients or group activities among patients
with sexual problems are also needed.
Based on the results of this study, we attempted con-
firm that the health status of patients with COPD
changes according to their characteristics over time,
even if their baseline conditions are similar when they
first visit a medical institution. When healthcare profes-
sionals first encounter a COPD patient in the clinical
setting, they identify and predict the condition based on
the patient’s baseline data. The healthcare professionals’
understanding and awareness of longitudinal changes
are highly important for the continuity of care and pro-
gress. Therefore, we expected that our study findings
would be helpful in planning patient-centered care. For
this reason, we analyzed and presented the factors
influencing the baseline data in this study. Although this
study analyzed longitudinal data collected over 4 years,
COPD is a lifelong disease, as it progresses gradually. It
is important to observe the progression of health status
for a longer period of time, reflecting the progressive na-
ture of COPD. These long-term analyses need to be per-
formed consistently using large-scale national-based data
rather than by a single medical institution or individual
research team.
Comprehensive assessment and multidimensional
monitoring could contribute to the early detection of pa-
tients at risk of lower erectile function and QoL, which
would allow for earlier intervention. In particular, in
Asian cultures including Korea, both medical personnel
and patients have a passive attitude toward sexual health
problems, making it difficult to implement individual-
ized care for sexual function problems. For policy rec-
ommendations, in cases of outpatient departments or
inpatient wards that are frequently visited by individuals
with chronic diseases, such as COPD, the involvement
of sex counseling specialists or trained nurse practi-
tioners could facilitate consultation. Moreover, it is ne-
cessary to reduce the burden of medical expenses for
patients by converting the medical expenses incurred for
the sexual function consultation into medical insurance
benefit items. In particular, it seems necessary to link the
resources available through consultation for low-income
families and collaborate with social work teams.
If the sexual function-related factors identified in this
study are used appropriately and systematically clinically,
healthcare professionals will be able to evaluate the pa-
tient’s sexual health as well as perform regular and con-
tinuous monitoring of the respiratory symptoms of
COPD patients. It will also provide a basis for decision-
making and defining patient outcomes in patient-cen-
tered management.
This study had several limitations. First, it was a sec-
ondary data analysis using cohort data, and only the data
of patients who were registered to the cohort could be
analyzed; therefore, there is the possibility of selection
bias, and the sample size was limited. Because this study
was analyzed using the Korean cohort (KOLD) data that
recruited patients with obstructive lung disease, it was
not possible to make a comparative analysis with non-
COPD groups or healthy general populations. In the
future, it will be necessary to carry out a comparative
analysis with large nation-based data sets such as the
Korean National Health and Nutrition Examination
Survey or National Health Insurance. In addition,
despite having erectile dysfunction, subjects who were
taking medications that affect erectile function or par-
ticipating in a separate program for sexual functioning
were excluded from this study based on the exclusion
criteria, considering the influence of exogenous
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variables. Although some GMM analyses target large
numbers of samples using large national or multi-
national cohort data, some previous GMM analyses have
included a smaller number of samples when investigat-
ing specific health problems [27]. Due to the limited
number of samples registered in the cohort and the lim-
ited research variables, the present study did not obtain
the recommended number of subjects.
The results of this study may not be generalizable, as
the conservative culture of Korea hinders discussion of
sexual issues. Furthermore, some factors that can affect
patterns of changes in erectile function were not consid-
ered. The variation of erectile function among COPD
patients may be primarily affected by medication compli-
ance, continuity of follow-up observation, and changes in
patient condition, etc. It is necessary to analyze such
major situational changes and erectile function levels
simultaneously. Future studies should consider various
situational variables (time-varying variables) that change
with time. In this study, it was not possible to identify
whether changes in the patients’ condition, such as
changes in the physical functional status, changes in
medications and dosage, newly diagnosed diseases,
psychological status, economic status, health-related
behaviors (e.g., smoking cessation, regular exercise,
healthy food consumption, etc.) and life events (e.g.,
changes in family composition such as separation by
death, divorce, etc.), could have affected erectile function.
A dynamic model-based analysis is required to reflect the
time-varying variables. This requires a much larger sample
than that in the present study, and any influencing vari-
ables should be identified and systematically planned and
collected.
Conclusion
In this study, the erectile function of 185 men with
COPD tended to improve in the first year and then
worsen gradually over time despite treatment for COPD.
The contributing factors for the differences in baseline
erectile function among male COPD patients were older
age, poorer economic status, higher BODE index and
poorer self-rated health status. Using GMM, we identi-
fied four distinct latent groups as follows: “consistently
maintained normal erectile function” (9.7%), “rapidly
worsened and then rapidly improved” (9.2%), “gradually
improved in the early stage and then gradually wors-
ened” (36.8%), and “consistently maintained poor erectile
function” (44.3%). Progression of erectile function was
significantly associated with age, economic status, and
self-rated health status. This study is meaningful, in that
it overcame the limitations of the previous cross-sec-
tional studies that considered COPD patients as a homo-
geneous group, and longitudinally investigated changes
in the health status of the participants and identified
predictors of erectile dysfunction.
These findings are beneficial for understanding the effi-
cacy of a treatment process and introducing appropriate
patient-centered interventions. Physicians and clinical
nurses can identify groups at risk of erectile dysfunction
and provide appropriate preventive interventions that
could reduce the risk or enhance protective factors, which
could prevent depression and reduced QoL due to sexual
health problems. By identifying diverse personal factors
that affect the overall health status, rather than focusing
solely on respiratory symptoms, a broader understanding
of the chronic illness process can be gained, thereby en-
hancing the quality of patient-centered care. These strat-
egies may improve the sexual health and QoL of male
COPD patients and may contribute to cost-effective and
efficient patient care management.
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